AstraZeneca Results Presentation Deck
Forward-looking statements
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the
Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations,
performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or
other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by
their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different
from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the
Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words
'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially
from those contained forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or
delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or
approval; the risk of failure to obtain, defend and enforce effective IP protection and IP challenges by third parties; the impact of competitive pressures
including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political
pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the quality or execution of the
Group's commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the
impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical
processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and
capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being
questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery
and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the
occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that the COVID-19 global pandemic may have or
continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial
condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.
B
2View entire presentation